The OncoAlert Network 🚨
@oncoalert.bsky.social
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
www.OncoAlert360.com
www.OncoAlert360.com
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 28, 2025 at 5:45 PM
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
Join us LIVE for a special Springer Medicine webinar exploring the rising burden of colorectal cancer in younger adults REGISTER👉 www.springermedicine.com/webinar-prog...
Thursday, 11 December 2025 (18:00–19:30 CET) FREE & Online
. #ColorectalCancer
Thursday, 11 December 2025 (18:00–19:30 CET) FREE & Online
. #ColorectalCancer
November 28, 2025 at 4:03 PM
Join us LIVE for a special Springer Medicine webinar exploring the rising burden of colorectal cancer in younger adults REGISTER👉 www.springermedicine.com/webinar-prog...
Thursday, 11 December 2025 (18:00–19:30 CET) FREE & Online
. #ColorectalCancer
Thursday, 11 December 2025 (18:00–19:30 CET) FREE & Online
. #ColorectalCancer
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology NEXT WEEK IN LISBON info here👉https://buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer
November 28, 2025 at 3:32 PM
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology NEXT WEEK IN LISBON info here👉https://buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer
The OncoAlert 🚨TOP STACK: MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
November 26, 2025 at 5:59 PM
The OncoAlert 🚨TOP STACK: MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
Durvalumab combined with standard FLOT chemotherapy has received US 🇺🇸approval for treating adults with resectable, early to locally advanced gastric and gastroesophageal junction cancers, based on the MATTERHORN
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
November 26, 2025 at 4:28 PM
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
FDA Approval for durvalumab combined with FLOT in #GastricCancer
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
November 25, 2025 at 7:29 PM
FDA Approval for durvalumab combined with FLOT in #GastricCancer
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
Based on MATTEHORN
Source: AstraZeneca
www.astrazeneca.com/media-centre...
Durvalumab combined wi/ FLOT chemotherapy has received US approval for treating adults with resectable, early to locally advanced gastric and GEJ cancers
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 24, 2025 at 7:17 PM
MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org/events/medtalk
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FDA🇺🇸 approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive #BladderCancer
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
November 21, 2025 at 6:19 PM
FDA🇺🇸 approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive #BladderCancer
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
www.fda.gov/drugs/resour...
The approval is based on the phase 3 KEYNOTE-905/EV-303 trial, which randomized 344 patients to perioperative pembrolizumab plus enfortumab vedotin versus immediate surgery
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
November 19, 2025 at 4:40 PM
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉 buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
November 19, 2025 at 4:14 PM
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉 buff.ly/QJgM3QV
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
November 18, 2025 at 5:02 PM
NEWS FROM INDUSTRY
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
UPDATE: lidERA Trial In #BreastCancer
Source: Roche
www.roche.com/media/releas...
Roche announced that its phase III lidERA study of the investigational SERD giredestrant in ER-positive, HER2-negative early-stage breast cancer met its primary endpoint at an interim analysis
Join @Achard_Verane and @BertrandTOMBAL for this Manuscript2Practice series on postoperative #ProstateCancer recurrence ⭐️WATCH HERE👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at @mirrorsmed
brought to you by our collaborators at @mirrorsmed
November 17, 2025 at 4:25 PM
Join @Achard_Verane and @BertrandTOMBAL for this Manuscript2Practice series on postoperative #ProstateCancer recurrence ⭐️WATCH HERE👉 mirrorsmed.org/m2p-postoper...
brought to you by our collaborators at @mirrorsmed
brought to you by our collaborators at @mirrorsmed
DAY Three #CFS25 🚨
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 8:07 PM
DAY Three #CFS25 🚨
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three of #CFS25 🚨
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 6:55 PM
DAY Three of #CFS25 🚨
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three #CFS25 🚨
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 3:10 PM
DAY Three #CFS25 🚨
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 14, 2025 at 2:30 PM
Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
November 13, 2025 at 3:55 PM
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨Will be live on location
#ProstateCancer #BladderCancer #KidneyCancer
DAY Two of #CFS25 🚨
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
November 13, 2025 at 2:55 PM
DAY Two of #CFS25 🚨
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Day One of #CFS25 🚨
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
November 12, 2025 at 8:05 PM
Day One of #CFS25 🚨
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Day One of #CFS25 🚨
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
November 12, 2025 at 3:40 PM
Day One of #CFS25 🚨
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day One of #CFS25
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
November 12, 2025 at 2:55 PM
Day One of #CFS25
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
Big News from #APCCC26
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
November 12, 2025 at 1:39 PM
Big News from #APCCC26
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
You have more time to submit your abstract. 🚨 NEW DEADLINE!
Creating new opportunities for younger investigators in advanced #ProstateCancer
📅 New deadline: 23 November 2025 CET 👉 onlineevent.ch/APCCC/abstra...
🎟️ Registration: onlineevent.ch/APCCC/2026
Silke & Aurelius
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
November 8, 2025 at 8:09 PM
Straight from #UromigosLive 2025
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
A GREAT discussion on ADC use in #BladderCancer
The possibility of Combination Trials, seeing the trade off between Toxicity and the Long Term Benefit
Complete Video Here x.com/Uromigos/sta...
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
November 7, 2025 at 1:47 PM
Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org
December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.
OncoAlert 🚨will be Live from Lisbon covering this Great meeting
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
November 7, 2025 at 1:41 PM
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...
What does it mean for clinical practice? How should it guide treatment decisions?
📺 Join Neal Shore, MD & Alicia Morgans, MD